Therapeutic interventions targeting beta amyloid pathogenesis in an aging dog model

Current Neuropharmacology

Volumn 9, Issue 4, 2011, Pages 651-661

  Martin, Sarah B ^a   Dowling, Amy L S ^a   Head, Elizabeth ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

A beta vaccination; Alzheimer's disease; BACE 1 inhibitors; Canine; Metal chelators; Statins

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1 42] VACCINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; ATORVASTATIN; BETA SECRETASE 1; BETA SECRETASE 1 INHIBITOR; BETA SECRETASE INHIBITOR; CHELATING AGENT; CLIOQUINOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DOG; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; VACCINATION;

EID: 82955220491     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911798376217     Document Type: Review

References (178)

1. Braak, H.; Braak, E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol., 1991, 82(4), 239-259.
2. Braak, H.; Braak, E.; Bohl, J. Staging of Alzheimer-related cortical destruction. Eur. Neurol., 1993, 33(6), 403-408.
3. Khachaturian, Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol., 1985, 42(11), 1097-1105.
4. Evans, D.A.; Funkenstein, H.H.; Albert, M.S.; Scherr, P.A.; Cook, N.R.; Chown, M.J.; Hebert, L.E.; Hennekens, C.H.; Taylor, J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA, 1989, 262(18), 2551-2556.
5. Mirra, S.S.; Heyman, A.; McKeel, D.; Sumi, S.M.; Crain, B.J.; Brownlee, L.M.; Vogel, F.S.; Hughes, J.P.; van Belle, G.; Berg, L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology, 1991, 41(4), 479-486.
6. Murphy, M.P.; LeVine, H., 3rd. Alzheimer's disease and the amyloid-beta peptide. J. Alzheimers Dis., 2010, 19(1), 311-323.
7. Selkoe, D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem., 1996, 271(31), 18295-18298.
8. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81(2), 741-766.
9. Antonarakis, S.E.; Lyle, R.; Dermitzakis, E.T.; Reymond, A.; Deutsch, S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat. Rev. Genet., 2004, 5(10), 725-738.
10. Lott, I.T.; Head, E.; Doran, E.; Busciglio, J. Beta-amyloid, oxidative stress and down syndrome. Curr. Alzheimer Res., 2006, 3(5), 521-528.
11. Leverenz, J.B.; Raskind, M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol., 1998, 150(2), 296-304.
12. Giaccone, G.; Tagliavini, F.; Linoli, G.; Bouras, C.; Frigerio, L.; Frangione, B.; Bugiani, O. Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci. Lett., 1989, 97(1-2), 232-238.
13. Mann, D.M. Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome. Neurobiol. Aging, 1989, 10(5), 397-399; discussion 412-394.
14. Iwatsubo, T.; Mann, D.M.; Odaka, A.; Suzuki, N.; Ihara, Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann. Neurol., 1995, 37(3), 294-299.
15. Lemere, C.A.; Blusztajn, J.K.; Yamaguchi, H.; Wisniewski, T.; Saido, T.C.; Selkoe, D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis., 1996, 3(1), 16-32.
16. Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Mant, R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericak-Vance, M.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 1991, 349(6311), 704-706.
17. Chartier-Harlin, M.C.; Crawford, F.; Houlden, H.; Warren, A.; Hughes, D.; Fidani, L.; Goate, A.; Rossor, M.; Roques, P.; Hardy, J.; Mullan, M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature, 1991, 353(6347), 844-846.
18. Murrell, J.; Farlow, M.; Ghetti, B.; Benson, M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science, 1991, 254(5028), 97-99.
19. Hendriks, L.; van Duijn, C.M.; Cras, P.; Cruts, M.; Van Hul, W.; van Harskamp, F.; Warren, A.; McInnis, M.G.; Antonarakis, S.E.; Martin, J.J.; Hofman, A.; van Broeckhoven, C. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet, 1992, 1(3), 218-221.
20. Rovelet-Lecrux, A.; Hannequin, D.; Raux, G.; Le Meur, N.; Laquerriere, A.; Vital, A.; Dumanchin, C.; Feuillette, S.; Brice, A.; Vercelletto, M.; Dubas, F.; Frebourg, T.; Campion, D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet., 2006, 38(1), 24-26.
21. Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science, 2010, 330(6012), 1774.
22. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185.
23. Elder, G.A.; Gama Sosa, M.A.; De Gasperi, R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J. Med., 2010, 77(1), 69-81.
24. Gotz, J.; Ittner, L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci., 2008, 9(7), 532-544.
25. Albert, M.S.; Funkenstein, H.H. Disorders of the Nervous System. In: Nervous System, 2nd ed. Asburg, A.K., McKhanney, G.M., McDonald, W.I., Eds.; Saunders Inc.: Philadelphia; 1992, pp. 598-611.
26. Petersen, R.C.; Smith, G.E.; Waring, S.C.; Ivnik, R.J.; Kokmen, E.; Tangelos, E.G. Aging, memory, and mild cognitive impairment. Int. Psychogeriatr., 1997, 9(Suppl 1), 65-69.
27. Petersen, R.C.; Smith, G.E.; Waring, S.C.; Ivnik, R.J.; Tangalos, E.G.; Kokmen, E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol., 1999, 56(3), 303-308.
28. Joseph, J.; Cole, G.; Head, E.; Ingram, D. Nutrition, brain aging, and neurodegeneration. J. Neurosci., 2009, 29(41), 12795-12801.
29. Zawia, N.H.; Lahiri, D.K.; Cardozo-Pelaez, F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic. Biol. Med., 2009, 46(9), 1241-1249.
30. Morris, J.C.; Storandt, M.; Miller, J.P.; McKeel, D.W.; Price, J.L.; Rubin, E.H.; Berg, L. Mild cognitive impairment represents earlystage Alzheimer disease. Arch. Neurol., 2001, 58(3), 397-405.
31. Knopman, D.S. The initial recognition and diagnosis of dementia. Am. J. Med., 1998, 104(4A), 2S-12S; discussion 39S-42S.
32. Brizzee, K.R.; Ordy, J.M.; Hofer, H.; Kaack, B. Animal models for the study of brain disease and aging changes in teh brain. In: Alzheimer's disease: Senile dementia and related disorders, Katzman, R.; Terry, R.D.; Bick, K.L.; Eds.; Raven: New York; 1978, pp. 515-554.
33. Mosier, J.E. Effect of aging on body systems of the dog. Vet. Clin. North Am. Small Anim. Pract., 1989, 19(1), 1-12.
34. Cummings, B.J.; Head, E.; Ruehl, W.; Milgram, N.W.; Cotman, C.W. The canine as an animal model of human aging and dementia. Neurobiol. Aging, 1996, 17(2), 259-268.
35. Blizard, D.A.; Klein, L.C.; Cohen, R.; McClearn, G.E. A novel mouse-friendly cognitive task suitable for use in aging studies. Behav. Genet., 2003, 33(2), 181-189.
36. Milgram, N.W.; Head, E.; Weiner, E.; Thomas, E. Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Behav. Neurosci., 1994, 108(1), 57-68.
37. Cotman, C.W.; Head, E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J. Alzheimers Dis., 2008, 15(4), 685-707.
38. Adams, B.; Chan, A.; Callahan, H.; Milgram, N.W. The canine as a model of human cognitive aging: recent developments. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2000, 24(5), 675-692.
39. Head, E.; Mehta, R.; Hartley, J.; Kameka, M.; Cummings, B.J.; Cotman, C.W.; Ruehl, W.W.; Milgram, N.W. Spatial learning and memory as a function of age in the dog. Behav. Neurosci., 1995, 109(5), 851-858.
40. Rapp, P.R. Visual discrimination and reversal learning in the aged monkey (Macaca mulatta). Behav. Neurosci., 1990, 104(6), 876-884.
41. Rapp, P.R.; Amaral, D.G. Evidence for task-dependent memory dysfunction in the aged monkey. J. Neurosci., 1989, 9(10), 3568 3576.
42. Rapp, P.R.; Amaral, D.G. Recognition memory deficits in a subpopulation of aged monkeys resemble the effects of medial temporal lobe damage. Neurobiol. Aging, 1991, 12(5), 481-486.
43. Walker, L.C.; Kitt, C.A.; Struble, R.G.; Wagster, M.V.; Price, D.L.; Cork, L.C. The neural basis of memory decline in aged monkeys. Neurobiol. Aging, 1988, 9(5-6), 657-666.
44. Davis, R.T. Old monkey behavior. Exp. Gerontol., 1978, 13(3-4), 237-250.
45. Russell, M.J.; Bobik, M.; White, R.G.; Hou, Y.; Benjamin, S.A.; Geddes, J.W. Age-specific onset of beta-amyloid in beagle brains. Neurobiol. Aging, 1996, 17(2), 269-273.
46. Bons, N.; Mestre, N.; Petter, A. Senile plaques and neurofibrillary changes in the brain of an aged lemurian primate, Microcebus murinus. Neurobiol. Aging, 1992, 13(1), 99-105.
47. Selkoe, D.J.; Bell, D.S.; Podlisny, M.B.; Price, D.L.; Cork, L.C. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science, 1987, 235(4791), 873-877.
48. Cummings, B.J.; Head, E.; Afagh, A.J.; Milgram, N.W.; Cotman, C.W. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol. Learn Mem., 1996, 66(1), 11-23.
49. Cummings, B.J.; Su, J.H.; Cotman, C.W.; White, R.; Russell, M.J. Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol. Aging, 1993, 14(6), 547-560.
50. Head, E.; McCleary, R.; Hahn, F.F.; Milgram, N.W.; Cotman, C.W. Region-specific age at onset of beta-amyloid in dogs. Neurobiol. Aging, 2000, 21(1), 89-96.
51. Head, E.; Torp, R. Insights into Abeta and presenilin from a canine model of human brain aging. Neurobiol. Dis., 2002, 9(1), 1-10.
52. Giaccone, G.; Verga, L.; Finazzi, M.; Pollo, B.; Tagliavini, F.; Frangione, B.; Bugiani, O. Cerebral preamyloid deposits and congophilic angiopathy in aged dogs. Neurosci. Lett., 1990, 114(2), 178-183.
53. Morys, J.; Narkiewicz, O.; Maciejewska, B.; Wegiel, J.; Wisniewski, H.M. Amyloid deposits and loss of neurones in the claustrum of the aged dog. Neuroreport, 1994, 5(14), 1825-1828.
54. Okuda, R.; Uchida, K.; Tateyama, S.; Yamaguchi, R.; Nakayama, H.; Goto, N. The distribution of amyloid beta precursor protein in canine brain. Acta Neuropathol., 1994, 87(2), 161-167.
55. Russell, M.J.; White, R.; Patel, E.; Markesbery, W.R.; Watson, C.R.; Geddes, J.W. Familial influence on plaque formation in the beagle brain. Neuroreport, 1992, 3(12), 1093-1096.
56. Uchida, K.; Tani, Y.; Uetsuka, K.; Nakayama, H.; Goto, N. Immunohistochemical studies on canine cerebral amyloid angiopathy and senile plaques. J. Vet. Med. Sci, 1992, 54(4), 659-667.
57. Markesbery, W.R.; Schmitt, F.A.; Kryscio, R.J.; Davis, D.G.; Smith, C.D.; Wekstein, D.R. Neuropathologic substrate of mild cognitive impairment. Arch. Neurol., 2006, 63(1), 38-46.
58. Morris, J.C.; Storandt, M.; McKeel, D.W., Jr.; Rubin, E.H.; Price, J.L.; Grant, E.A.; Berg, L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology, 1996, 46(3), 707-719.
59. Ishihara, T.; Gondo, T.; Takahashi, M.; Uchino, F.; Ikeda, S.; Allsop, D.; Imai, K. Immunohistochemical and immunoelectron microscopical characterization of cerebrovascular and senile plaque amyloid in aged dogs' brains. Brain Res., 1991, 548(1-2), 196-205.
60. Thal, D.R.; Rub, U.; Orantes, M.; Braak, H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58(12), 1791-1800.
61. Wisniewski, H.; Johnson, A.B.; Raine, C.S.; Kay, W.J.; Terry, R.D. Senile plaques and cerebral amyloidosis in aged dogs. A histochemical and ultrastructural study. Lab. Invest., 1970, 23(3), 287-296.
62. Attems, J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol., 2005, 110(4), 345-359.
63. Attems, J.; Jellinger, K.A.; Lintner, F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol., 2005, 110(3), 222-231.
64. Herzig, M.C.; Van Nostrand, W.E.; Jucker, M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol., 2006, 16(1), 40-54.
65. Prior, R.; D'Urso, D.; Frank, R.; Prikulis, I.; Pavlakovic, G. Loss of vessel wall viability in cerebral amyloid angiopathy. Neuroreport, 1996, 7(2), 562-564.
66. Tian, J.; Shi, J.; Mann, D.M. Cerebral amyloid angiopathy and dementia. Panminerva Med., 2004, 46(4), 253-264.
67. Uchida, K.; Nakayama, H.; Goto, N. Pathological studies on cerebral amyloid angiopathy, senile plaques and amyloid deposition in visceral organs in aged dogs. J. Vet. Med. Sci., 1991, 53(6), 1037-1042.
68. Selkoe, D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res., 2008, 192(1), 106-113.
69. Tomic, J.L.; Pensalfini, A.; Head, E.; Glabe, C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis., 2009, 35(3), 352-358.
70. McDonald, J.M.; Savva, G.M.; Brayne, C.; Welzel, A.T.; Forster, G.; Shankar, G.M.; Selkoe, D.J.; Ince, P.G.; Walsh, D.M. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain, 2010, 133(Pt 5), 1328-1341.
71. Pop, V.; Head, E.; Berchtold, N.C.; Glabe, C.G.; Studzinski, C.M.; Weidner, A.M.; Murphy, M.P.; Cotman, C.W. Abeta aggregation profiles and shifts in APP processing favor amyloidogenesis in canines. Neurobiol. Aging, 2010 [Epub a head of print]. doi:10. 1016/j.neurobiolaging.2010.02.008
72. Pugliese, M.; Gangitano, C.; Ceccariglia, S.; Carrasco, J.L.; Del Fa, A.; Rodriguez, M.J.; Michetti, F.; Mascort, J.; Mahy, N. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes. Brain Res., 2007, 1139, 85-94.
73. Dringenberg, H.C. Alzheimer's disease: more than a 'cholinergic disorder' evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav. Brain Res., 2000, 115(2), 235-249.
74. Grudzien, A.; Shaw, P.; Weintraub, S.; Bigio, E.; Mash, D.C.; Mesulam, M.M. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging, 2007, 28(3), 327-335.
75. Insua, D.; Suarez, M.L.; Santamarina, G.; Sarasa, M.; Pesini, P. Dogs with canine counterpart of Alzheimer's disease lose noradrenergic neurons. Neurobiol. Aging, 2010, 31(4), 625-635.
76. Wegiel, J.; Kuchna, I.; Nowicki, K.; Frackowiak, J.; Mazur Kolecka, B.; Imaki, H.; Mehta, P.D.; Silverman, W.P.; Reisberg, B.; Deleon, M.; Wisniewski, T.; Pirttilla, T.; Frey, H.; Lehtimaki, T.; Kivimaki, T.; Visser, F.E.; Kamphorst, W.; Potempska, A.; Bolton, D.; Currie, J.R.; Miller, D.L. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol., 2007, 113(4), 389-402.
77. Hartley, D.M.; Walsh, D.M.; Ye, C.P.; Diehl, T.; Vasquez, S.; Vassilev, P.M.; Teplow, D.B.; Selkoe, D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci., 1999, 19(20), 8876-8884.
78. Walsh, D.M.; Hartley, D.M.; Kusumoto, Y.; Fezoui, Y.; Condron, M.M.; Lomakin, A.; Benedek, G.B.; Selkoe, D.J.; Teplow, D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 1999, 274(36), 25945-25952.
79. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(11), 6448-6453.
80. Lesne, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 2006, 440(7082), 352-357.
81. Roher, A.E.; Chaney, M.O.; Kuo, Y.M.; Webster, S.D.; Stine, W.B.; Haverkamp, L.J.; Woods, A.S.; Cotter, R.J.; Tuohy, J.M.; Krafft, G.A.; Bonnell, B.S.; Emmerling, M.R. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem., 1996, 271(34), 20631-20635.
82. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci., 2007, 8(7), 499-509.
83. Middleton, L.E.; Yaffe, K. Promising strategies for the prevention of dementia. Arch. Neurol., 2009, 66(10), 1210-1215.
84. Lee, J.W.; Lee, Y.K.; Ban, J.O.; Ha, T.Y.; Yun, Y.P.; Han, S.B.; Oh, K.W.; Hong, J.T. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NFkappaB pathways in mice. J. Nutr., 2009, 139(10), 1987-1993.
85. Lim, G.P.; Calon, F.; Morihara, T.; Yang, F.; Teter, B.; Ubeda, O.; Salem, N., Jr.; Frautschy, S.A.; Cole, G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci., 2005, 25(12), 3032-3040.
86. Lazarov, O.; Robinson, J.; Tang, Y.P.; Hairston, I.S.; Korade Mirnics, Z.; Lee, V.M.; Hersh, L.B.; Sapolsky, R.M.; Mirnics, K.; Sisodia, S.S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell, 2005, 120(5), 701-713.
87. Churchill, J.D.; Galvez, R.; Colcombe, S.; Swain, R.A.; Kramer, A.F.; Greenough, W.T. Exercise, experience and the aging brain. Neurobiol. Aging, 2002, 23(5), 941-955.
88. Cotman, C.W.; Berchtold, N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci., 2002, 25(6), 295-301.
89. Engelhart, M.J.; Geerlings, M.I.; Ruitenberg, A.; van Swieten, J.C.; Hofman, A.; Witteman, J.C.; Breteler, M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA, 2002, 287(24), 3223-3229.
90. Morris, M.C.; Evans, D.A.; Bienias, J.L.; Tangney, C.C.; Wilson, R.S. Vitamin E and cognitive decline in older persons. Arch. Neurol., 2002, 59(7), 1125-1132.
91. Erickson, K.I.; Kramer, A.F. Aerobic exercise effects on cognitive and neural plasticity in older adults. Br. J. Sports Med., 2009, 43(1), 22-24.
92. Willis, S.L.; Tennstedt, S.L.; Marsiske, M.; Ball, K.; Elias, J.; Koepke, K.M.; Morris, J.N.; Rebok, G.W.; Unverzagt, F.W.; Stoddard, A.M.; Wright, E. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA, 2006, 296(23), 2805-2814.
93. Ball, K.; Berch, D.B.; Helmers, K.F.; Jobe, J.B.; Leveck, M.D.; Marsiske, M.; Morris, J.N.; Rebok, G.W.; Smith, D.M.; Tennstedt, S.L.; Unverzagt, F.W.; Willis, S.L. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA, 2002, 288(18), 2271-2281.
94. Milgram, N.W.; Zicker, S.C.; Head, E.; Muggenburg, B.A.; Murphey, H.; Ikeda-Douglas, C.J.; Cotman, C.W. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol. Aging, 2002, 23(5), 737-745.
95. Milgram, N.W.; Head, E.; Zicker, S.C.; Ikeda-Douglas, C.J.; Murphey, H.; Muggenburg, B.; Siwak, C.; Tapp, D.; Cotman, C.W. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol. Aging, 2005, 26(1), 77-90.
96. Pop, V.; Head, E.; Berchtold, N.C.; Glabe, C.; Studzinski, C.M.; Weidner, A.M.; Murphy, M.P.; Cotman, C.W. Beta-amyloid aggregation profiles and shifts in APP processing favor amyloidogenesis in canines. Neurobiol. Aging, 2010. doi:10.1016/ j.neurobiolaging.2010.02.008
97. Fukumoto, H.; Cheung, B.S.; Hyman, B.T.; Irizarry, M.C. Betasecretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol, 2002, 59(9), 1381-1389.
98. Yang, L.B.; Lindholm, K.; Yan, R.; Citron, M.; Xia, W.; Yang, X.L.; Beach, T.; Sue, L.; Wong, P.; Price, D.; Li, R.; Shen, Y. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med., 2003, 9(1), 3-4.
99. Li, R.; Lindholm, K.; Yang, L.B.; Yue, X.; Citron, M.; Yan, R.; Beach, T.; Sue, L.; Sabbagh, M.; Cai, H.; Wong, P.; Price, D.; Shen, Y. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(10), 3632-3637.
100. Vassar, R.; Kovacs, D.M.; Yan, R.; Wong, P.C. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci., 2009, 29(41), 12787-12794.
101. Stefansson, H.; Sigurdsson, E.; Steinthorsdottir, V.; Bjornsdottir, S.; Sigmundsson, T.; Ghosh, S.; Brynjolfsson, J.; Gunnarsdottir, S.; Ivarsson, O.; Chou, T.T.; Hjaltason, O.; Birgisdottir, B.; Jonsson, H.; Gudnadottir, V.G.; Gudmundsdottir, E.; Bjornsson, A.; Ingvarsson, B.; Ingason, A.; Sigfusson, S.; Hardardottir, H.; Harvey, R.P.; Lai, D.; Zhou, M.; Brunner, D.; Mutel, V.; Gonzalo, A.; Lemke, G.; Sainz, J.; Johannesson, G.; Andresson, T.; Gudbjartsson, D.; Manolescu, A.; Frigge, M.L.; Gurney, M.E.; Kong, A.; Gulcher, J.R.; Petursson, H.; Stefansson, K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet., 2002, 71(4), 877-892.
102. Gerlai, R.; Pisacane, P.; Erickson, S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav. Brain Res., 2000, 109(2), 219-227.
103. McConlogue, L.; Buttini, M.; Anderson, J.P.; Brigham, E.F.; Chen, K.S.; Freedman, S.B.; Games, D.; Johnson-Wood, K.; Lee, M.; Zeller, M.; Liu, W.; Motter, R.; Sinha, S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J. Biol. Chem., 2007, 282(36), 26326-26334.
104. Jick, H.; Zornberg, G.L.; Jick, S.S.; Seshadri, S.; Drachman, D.A. Statins and the risk of dementia. Lancet, 2000, 356(9242), 1627-1631.
105. Wolozin, B.; Kellman, W.; Ruosseau, P.; Celesia, G.G.; Siegel, G. Decreased prevalence of Alzheimer disease associated with 3 hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 2000, 57(10), 1439-1443.
106. Rockwood, K.; Kirkland, S.; Hogan, D.B.; MacKnight, C.; Merry, H.; Verreault, R.; Wolfson, C.; McDowell, I. Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwelling elderly people. Arch. Neurol., 2002, 59(2), 223-227.
107. Hajjar, I.; Schumpert, J.; Hirth, V.; Wieland, D.; Eleazer, G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A Biol. Sci. Med. Sci., 2002, 57(7), M414-418.
108. Rodriguez, E.G.; Dodge, H.H.; Birzescu, M.A.; Stoehr, G.P.; Ganguli, M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J. Am. Geriatr. Soc., 2002, 50(11), 1852-1856.
109. Dufouil, C.; Richard, F.; Fievet, N.; Dartigues, J.F.; Ritchie, K.; Tzourio, C.; Amouyel, P.; Alperovitch, A. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology, 2005, 64(9), 1531-1538.
110. Zamrini, E.; McGwin, G.; Roseman, J.M. Association between statin use and Alzheimer's disease. Neuroepidemiology, 2004, 23(1 2), 94-98.
111. Wolozin, B.; Wang, S.W.; Li, N.C.; Lee, A.; Lee, T.A.; Kazis, L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med, 2007, 5, 20.
112. Li, G.; Higdon, R.; Kukull, W.A.; Peskind, E.; Van Valen Moore, K.; Tsuang, D.; van Belle, G.; McCormick, W.; Bowen, J.D.; Teri, L.; Schellenberg, G.D.; Larson, E.B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology, 2004, 63(9), 1624-1628.
113. Rea, T.D.; Breitner, J.C.; Psaty, B.M.; Fitzpatrick, A.L.; Lopez, O.L.; Newman, A.B.; Hazzard, W.R.; Zandi, P.P.; Burke, G.L.; Lyketsos, C.G.; Bernick, C.; Kuller, L.H. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol., 2005, 62(7), 1047-1051.
114. Zandi, P.P.; Sparks, D.L.; Khachaturian, A.S.; Tschanz, J.; Norton, M.; Steinberg, M.; Welsh-Bohmer, K.A.; Breitner, J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry, 2005, 62(2), 217-224.
115. Haag, M.D.; Hofman, A.; Koudstaal, P.J.; Stricker, B.H.; Breteler, M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry, 2009, 80(1), 13-17.
116. Rockwood, K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol. Scand Suppl., 2006, 185, 71-77.
117. Sparks, L. Statins and cognitive function. J. Neurol. Neurosurg. Psychiatry, 2009, 80(1), 1-2.
118. Simons, M.; Schwarzler, F.; Lutjohann, D.; von Bergmann, K.; Beyreuther, K.; Dichgans, J.; Wormstall, H.; Hartmann, T.; Schulz, J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebocontrolled, double-blind trial. Ann. Neurol., 2002, 52(3), 346-350.
119. Sparks, D.L.; Connor, D.J.; Sabbagh, M.N.; Petersen, R.B.; Lopez, J.; Browne, P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand Suppl, 2006, 185, 3-7.
120. Sparks, D.L.; Sabbagh, M.N.; Connor, D.J.; Lopez, J.; Launer, L.J.; Petanceska, S.; Browne, P.; Wassar, D.; Johnson-Traver, S.; Lochhead, J.; Ziolkowski, C. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res., 2005, 2(3), 343-353.
121. Sparks, D.L.; Sabbagh, M.N.; Connor, D.J.; Lopez, J.; Launer, L.J.; Browne, P.; Wasser, D.; Johnson-Traver, S.; Lochhead, J.; Ziolwolski, C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol., 2005, 62(5), 753-757.
122. Sparks, D.L.; Sabbagh, M.; Connor, D.; Soares, H.; Lopez, J.; Stankovic, G.; Johnson-Traver, S.; Ziolkowski, C.; Browne, P. Statin therapy in Alzheimer's disease. Acta Neurol. Scand. Suppl, 2006, 185, 78-86.
123. Pappolla, M.A. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology, 2008, 71(24), 2020; author reply 2020-2021.
124. Solomon, A.; Kareholt, I.; Ngandu, T.; Wolozin, B.; Macdonald, S.W.; Winblad, B.; Nissinen, A.; Tuomilehto, J.; Soininen, H.; Kivipelto, M. Serum total cholesterol, statins and cognition in nondemented elderly. Neurobiol. Aging, 2009, 30(6), 1006-1009.
125. Cramer, C.; Haan, M.N.; Galea, S.; Langa, K.M.; Kalbfleisch, J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology, 2008, 71(5), 344 350.
126. Simons, M.; Keller, P.; Strooper, B.D.; Beyreuther, K.; Dotti, C.G.; Simons, K. Cholesterol depletion inhibits the generation of betaamyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA, 1998, 95, 6460-6464.
127. Hartmann, T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci., 2001, 24(11 Suppl), S45-48.
128. Petanceska, S.S.; DeRosa, S.; Olm, V.; Diaz, N.; Sharma, A.; Thomas-Bryant, T.; Duff, K.; Pappolla, M.; Refolo, L.M. Statin therapy for Alzheimer's disease: will it work? J. Mol. Neurosci., 2002, 19(1-2), 155-161.
129. Alberts, A.W. Lovastatin and simvastatin inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology, 1990, 77(4), 14-21.
130. Fears, R.; Richards, D.H.; Ferres, H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylgutaryl co-enzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis, 1980, 35(4), 439-449.
131. Todd, P.A.; Goa, K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs, 1990, 40(4), 583-607.
132. Thelen, K.M.; Rentsch, K.M.; Gutteck, U.; Heverin, M.; Olin, M.; Andersson, U.; von Eckardstein, A.; Bjorkhem, I.; Lutjohann, D. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther., 2006, 316(3), 1146-1152.
133. Gerson, R.J.; MacDonald, J.S.; Alberts, A.W.; Kornbrust, D.J.; Majka, J.A.; Stubbs, R.J.; Bokelman, D.L. Animal safety and toxicology of simvastatin and related hydroxy-methylglutarylcoenzyme A reductase inhibitors. Am. J. Med., 1989, 87(4A), 28S 38S.
134. Bush, A.I.; Pettingell, W.H.; Multhaup, G.; d Paradis, M.; Vonsattel, J.P.; Gusella, J.F.; Beyreuther, K.; Masters, C.L.; Tanzi, R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science, 1994, 265(5177), 1464-1467.
135. Bush, A.I.; Pettingell, W.H., Jr.; Paradis, M.D.; Tanzi, R.E. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J. Biol. Chem., 1994, 269(16), 12152-12158.
136. Ha, C.; Ryu, J.; Park, C.B. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry, 2007, 46(20), 6118-6125.
137. Noy, D.; Solomonov, I.; Sinkevich, O.; Arad, T.; Kjaer, K.; Sagi, I. Zinc-amyloid beta interactions on a millisecond time-scale stabilize non-fibrillar Alzheimer-related species. J. Am. Chem. Soc., 2008, 130(4), 1376-1383.
138. Sensi, S.L.; Paoletti, P.; Bush, A.I.; Sekler, I. Zinc in the physiology and pathology of the CNS. Nat. Rev. Neurosci., 2009, 10(11), 780-791.
139. Grundke-Iqbal, I.; Fleming, J.; Tung, Y.C.; Lassmann, H.; Iqbal, K.; Joshi, J.G. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol., 1990, 81(2), 105-110.
140. Quinn, J.F.; Crane, S.; Harris, C.; Wadsworth, T.L. Copper in Alzheimer's disease: too much or too little? Expert Rev. Neurother., 2009, 9(5), 631-637.
141. Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, W.D.; McLean, C.A.; Barnham, K.J.; Volitakis, I.; Fraser, F.W.; Kim, Y.; Huang, X.; Goldstein, L.E.; Moir, R.D.; Lim, J.T.; Beyreuther, K.; Zheng, H.; Tanzi, R.E.; Masters, C.L.; Bush, A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 2001, 30(3), 665-676.
142. Adlard, P.A.; Cherny, R.A.; Finkelstein, D.I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J.P.; Perez, K.; Laughton, K.; Li, Q.X.; Charman, S.A.; Nicolazzo, J.A.; Wilkins, S.; Deleva, K.; Lynch, T.; Kok, G.; Ritchie, C.W.; Tanzi, R.E.; Cappai, R.; Masters, C.L.; Barnham, K.J.; Bush, A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 2008, 59(1), 43-55.
143. Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R.E.; Masters, C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol., 2003, 60(12), 1685-1691.
144. Jenagaratnam, L.; McShane, R. Clioquinol for the treatment of Alzheimer's Disease. Cochrane Database Syst. Rev., 2006, (1), CD005380.
145. Sampson, E.; Jenagaratnam, L.; McShane, R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev., 2008, (1), CD005380.
146. Barden, H. The histochemical distribution and localization of copper, iron, neuromelanin and lysosomal enzyme activity in the brain of aging rhesus monkey and the dog. J. Neuropathol. Exp. Neurol., 1971, 30(4), 650-667.
147. Das, P.; Howard, V.; Loosbrock, N.; Dickson, D.; Murphy, M.P.; Golde, T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/ knock-out mice. J. Neurosci., 2003, 23(24), 8532-8538.
148. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St George-Hyslop, P.; Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408(6815), 979-982.
149. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408(6815), 982-985.
150. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandervert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. Immunization with amyloid-IIIattentuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-177.
151. Sigurdsson, E.M.; Knudsen, E.; Asuni, A.; Fitzer-Attas, C.; Sage, D.; Quartermain, D.; Goni, F.; Frangione, B.; Wisniewski, T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci, 2004, 24(28), 6277-6282.
152. Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; Paul, S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci., 2002, 5(5), 452-457.
153. Kotilinek, L.A.; Bacskai, B.; Westerman, M.; Kawarabayashi, T.; Younkin, L.; Hyman, B.T.; Younkin, S.; Ashe, K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci., 2002, 22(15), 6331-6335.
154. Morley, J.E.; Farr, S.A.; Flood, J.F. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol. Learn Mem., 2002, 78(1), 125-138.
155. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 2004, 24(27), 6144 6151.
156. Head, E.; Pop, V.; Vasilevko, V.; Hill, M.; Saing, T.; Sarsoza, F.; Nistor, M.; Christie, L.A.; Milton, S.; Glabe, C.; Barrett, E.; Cribbs, D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci., 2008, 28(14), 3555-3566.
157. Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61(1), 46-54.
158. Hock, C.; Konietzko, U.; Streffer, J.R.; Tracy, J.; Signorell, A.; Muller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, E.; Wollmer, M.A.; Umbricht, D.; de Quervain, D.J.; Hofmann, M.; Maddalena, A.; Papassotiropoulos, A.; Nitsch, R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003, 38(4), 547-554.
159. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64(9), 1553-1562.
160. Ferrer, I.; Boada Rovira, M.; Sanchez Guerra, M.L.; Rey, M.J.; Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol., 2004, 14(1), 11-20.
161. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 9(4), 448-452.
162. Masliah, E.; Hansen, L.; Adame, A.; Crews, L.; Bard, F.; Lee, C.; Seubert, P.; Games, D.; Kirby, L.; Schenk, D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 2005, 64(1), 129-131.
163. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
164. Lai, Z.C.; Moss, M.B.; Killiany, R.J.; Rosene, D.L.; Herndon, J.G. Executive system dysfunction in the aged monkey: spatial and object reversal learning. Neurobiol. Aging, 1995, 16, 947-954.
165. Cronin-Golomb, A. Color vision, object recognition, and spatial localization in aging and Alzheimer's disease. In: Functional Neurobiology of Aging, Hof, P.R., Mobbs, C.V., Eds.; Academic Press: San Diego; 2001, pp. 517-529.
166. Boutet, I.; Milgram, N.W.; Freedman, M. Cognitive decline and human (Homo sapiens) aging: an investigation using a comparative neuropsychological approach. J. Comp. Psychol., 2007, 121(3), 270-281.
167. Freedman, M.; Oscar-Berman, M. Spatial and visual learning deficits in Alzheimer's disease and Parkinson's disease. Brain Cognit., 1989, 11, 114-126.
168. Emborg, M.E.; Ma, S.Y.; Mufson, E.J.; Levey, A.I.; Taylor, M.D.; Brown, W.D.; Holden, J.E.; Kordower, J.H. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol., 1998, 401(2), 253-265.
169. Kordower, J.H.; Liu, Y.T.; Winn, S.; Emerich, D.F. Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical, and neurochemical analysis. Cell Transplant., 1995, 4(2), 155-171.
170. Christie, L.A.; Studzinski, C.M.; Araujo, J.A.; Leung, C.S.; Ikeda Douglas, C.J.; Head, E.; Cotman, C.W.; Milgram, N.W. A comparison of egocentric and allocentric age-dependent spatial learning in the beagle dog. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(3), 361-369.
171. Mishkin, M.; Delacour, J. An analysis of short-term visual memory in the monkey. J. Exper. Psychol: Anim. Behav. Proc., 1975, 1, 326-334.
172. Lezak, M.D.; Howieson, D.B.; Loring, D.W. Neuropsychological Assessment. Oxford University Press: New York,2004.
173. Arnsten, A.F.T., and Goldman-Rakic, P.S. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science, 1985, 230, 1273-1276.
174. Kowalska, D.M. Effects of hippocampal lesions on spatial delayed responses in dog. Hippocampus, 1995, 5(4), 363-370.
175. Warren, J.M. The behavior of carnivores and primates with lesions in the prefrontal cortex. In: The Frontal Granular Cortex and Behavior, Warren, J.M., Akert, K., Eds.; McGraw-Hill Book Company: New York; 1964, pp. 168-191.
176. Kramer, J.H.; Quitania, L. Bedside Frontal Lobe Testing. In: The Human Frontal Lobes, Miller, B.L., Cummings, J.L., Ed.; The Guilford Press: New York; 2007, pp. 279-291.
177. Rapp, P.R.; Kansky, M.T.; Eichenbaum, H. Learning and memory for hierarchical relationships in the monkey: effects of aging. Behav. Neurosci., 1996, 110(5), 887-897.
178. Pohl, W. Dissociation of spatial discrimination deficits following frontal and parietal lesions in monkeys. J. Comp. Physiol. Psychol., 1973, 82, 227-239.